CURE250117C127000
- 0.00
- 0.000.00%
Direxion Daily Healthcare Bull 3X Shares Newsroom
CMS Proposes 4.33% Increase for Medicare Advantage Plans
SpringWorks Therapeutics Jumps Amid Takeover Speculation
Catalyst Watch: Bank Earnings, Oil Updates, Powerhouse Conferences in Retail and Healthcare
Lilly Signs Licensing Deal With Mediar for IPF Drug
"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times
UnitedHealth Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AbbVie Unusual Options Activity For January 10
HIMS Downgraded, Agilon Upgraded at Citi in 2025 Health Tech Review
On Thursday, Alchemab Therapeutics Entered A Collaboration With Eli Lilly To Discover, Develop, And Commercialize Up To Five Therapeutics For Amyotrophic Lateral Sclerosis; Alchemab Will Receive An Undisclosed Upfront Payment And Is Eligible To...
Morgan Stanley's outlook for the top ten investment trends in 2025: the revival of nuclear energy, the AI revolution in the financial Industry, quantum computing, oral weight loss medications...
Morgan Stanley pointed out that historically, popular themes with strong profit momentum tend to have a strong sustainability, such as AI, defense spending, and obesity drugs; negative prices and quantum computing are expected to emerge as new investment hotspots.
Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Drugs Not Selected for Medicare Price Negotiation Nearly Doubled - Report
Evaluating UnitedHealth Group Against Peers In Health Care Providers & Services Industry
Novo, Eli Lilly to Dominate Global Pharma Sales in 2025: Report
UnitedHealth Urged by Investors to Review Insurance Practices
Musk: The goal this year is to produce thousands of Siasun Robot&Automation humanoid robots, with production increasing tenfold each year over the next two years.
Musk stated that if everything goes smoothly, the production of humanoid robots will increase tenfold by 2026, with the goal of producing between 0.05 million to 0.1 million humanoid robots next year, and then increasing it tenfold again the following year.
'Medicare Can Now Cover Eli Lilly's Zepbound For Sleep Apnea, CMS Says' - CNBC
Assessing AbbVie: Insights From 17 Financial Analysts